D. Claremon

发表

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

E. A. O'neill, J. Vacca, B. Frantz, 1999, Journal of Medicinal Chemistry.

NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.

Menghang Xia, Bohumil Bednar, Kenneth D Anderson, 2004, Journal of medicinal chemistry.

Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.

K. Fan, R. Gregg, Suresh B. Singh, 2016, Bioorganic & medicinal chemistry letters.

Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.

K. Fan, R. Gregg, Zhijie Liu, 2016, Journal of medicinal chemistry.

Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.

R. Bentley, C. Doe, Suresh B. Singh, 2011, Bioorganic & medicinal chemistry letters.

Antihypertensives: Renin Inhibitors

D. Claremon, C. Tice, G. Mcgeehan, 2010 .

Preparation of 3-amino-1,4-benzodiazepin-2-ones via direct azidation with trisyl azide

N. Liverton, A. Tebben, H. Selnick, 1996 .

An electronic environment and contact direction sensitive scoring function for predicting affinities of protein-ligand complexes in Contour(®).

Kam-Chuen Jim, R. Gregg, Zhijie Liu, 2014, Journal of molecular graphics & modelling.

Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia.

G. Billman, N. Liverton, A. Tebben, 1999, Circulation.

Serum‐induced monocyte differentiation and monocyte chemotaxis are regulated by the p38 MAP kinase signal transduction pathway

S. O'keefe, N. Liverton, W. Hanlon, 2000, Journal of leukocyte biology.

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

E. A. O'neill, J. Vacca, B. Frantz, 1999, Journal of medicinal chemistry.

Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1.

Suresh B. Singh, P. Carroll, D. Claremon, 2011, Journal of medicinal chemistry.

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.

K. Ross, S. Armstrong, Heather J. Lee, 2019, Cancer cell.

Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.

H. Nar, B. Hamilton, D. Lala, 2015, European journal of pharmacology.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.

J. Baldwin, R. Gould, G. Hartman, 1997, The Journal of pharmacology and experimental therapeutics.

Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide.

J J Baldwin, M. Sanguinetti, R. Freidinger, 1997, Journal of medicinal chemistry.

Effects of New and Potent Methanesulfonanilide Class III Antiarrhythmic Agents on Myocardial Refractoriness and Contractility in Isolated Cardiac Muscle

H. Selnick, J. Lynch, D. Claremon, 1991, Journal of cardiovascular pharmacology.

Cardiac Electrophysiologic and Inotropic Actions of New and Potent Methanesulfonanilide Class III Antiarrhythmic Agents in Anesthetized Dogs

H. Selnick, J. Lynch, D. Claremon, 1991, Journal of cardiovascular pharmacology.

Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.

B. Hamilton, D. Lala, D. Claremon, 2016, European journal of pharmacology.

Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation.

A. Stern, J. Baldwin, K. Freund, 1994, Biochemistry.

154 A novel factor XIIIa inhibitor enhances clot lysis rates

A. Stern, J. Baldwin, K. Freund, 1988 .

Nonpeptide glycoprotein IIb/IIIa inhibitors: substituted quinazolinediones and quinazolinones as potent fibrinogen receptor antagonists.

N. Liverton, J. Baldwin, R. Gould, 1998, Bioorganic & medicinal chemistry letters.

Nonpeptide glycoprotein IIb/IIIa inhibitors. 13. design and synthesis of an orally active pyrazolopiperazinone nonpeptide fibrinogen receptor antagonist

P. Anderson, J. Baldwin, R. Gould, 1997 .

Non-peptide glycoprotein IIb/IIIa inhibitors. 6. Design and synthesis of rigid, centrally constrained non-peptide fibrinogen receptor antagonists

R. Gould, D. Claremon, C. A. Hunt, 1995 .

Carbocyclic thromboxane A2: aggrevation of myocardial ischemia by a new synthetic thromboxane A2 analog.

A. M. Lefer, E. Smith, R. Magolda, 1981, Prostaglandins.

Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.

Suresh B. Singh, B. Hamilton, D. Lala, 2017, Bioorganic & medicinal chemistry.

Inhibition of factor XIIIa in a canine model of coronary thrombosis: effect on reperfusion and acute reocclusion after recombinant tissue-type plasminogen activator.

A. Stern, J. Baldwin, D. Claremon, 1990, Blood.

Process Development of the BACE Inhibitors BI 1147560 BS and BI 1181181 MZ

Jinhua J. Song, S. Venkatraman, C. Senanayake, 2022, Organic Process Research & Development.

Chapter 11:Structure-based Design Technology CONTOUR and its Application to Drug Discovery

Zhijie Liu, Suresh B. Singh, Peter Lindblom, 2012 .

A mild method for the synthesis of 2-ketopyrroles from carboxylic acids

K. Nicolaou, D. Claremon, D. Papahatjis, 1982 .

N-phenylselenophthalimide (NPSP) : A valuable selenenylating agent

K. Nicolaou, N. Petasis, D. Claremon, 1985 .

An efficient chemoselective synthesis of nitriles from primary amides

B. T. Phillips, D. Claremon, 1988 .

Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.

A. Dilella, N. Liverton, C. Claiborne, 2007, Journal of medicinal chemistry.

Diethyl 3,6-dihydro-2,4-dimethyl-2,6-methano-1,3-benzothiazocine-5,11- dicarboxylates as calcium entry antagonists: new conformationally restrained analogues of Hantzsch 1,4-dihydropyridines related to nitrendipine as probes for receptor-site conformation.

G. M. Smith, P. Lumma, J. Baldwin, 1987, Journal of medicinal chemistry.

Novel Rigid Calcium-Entry Blockers: Intramolecular Reactions of 1,4-Dihydropyridine Derivatives.

J. Springer, J. Hirshfield, P. Lumma, 1986 .

Preparation of 7-alkyl-2,3,6,7-tetrahydro-4-alkyl-2-oxo-1H-1,3-diazepine-5-carboxylates by ring expansion-nucleophilic addition

D. Claremon, S. Rosenthal, 1986 .

SYNTHESIS OF 4,5-DIHYDROAZEPINE-3,6-DICARBOXYLATE DERIVATIVES BY STEREOSELECTIVE RING EXPANSION-NUCLEOPHILIC ADDITION TO 4-α-CHLOROALKYL-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLATES

J. Springer, J. Baldwin, D. Claremon, 1985 .

Total synthesis of ionophore antibiotic X-14547A

K. Nicolaou, R. Magolda, R. Dolle, 1985 .

N-Phenylselenophthalimide (N-PSP) and N-phenylselenosuccinimide (N-PSS). Two versatile carriers of the phenylseleno group. Oxyselenation of olefins and a selenium-based macrolide synthesis

K. Nicolaou, S. P. Seitz, D. Claremon, 1979 .

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists.

J. Baldwin, T. Prueksaritanont, R. Gould, 1997, Journal of medicinal chemistry.

Carbocyclic thromboxane A2

K. Nicolaou, R. Magolda, D. Claremon, 1980 .

Pyridazine based inhibitors of p38 MAPK.

S. O'keefe, N. Liverton, G. Ponticello, 2002, Bioorganic & medicinal chemistry letters.

Total synthesis of ionophore antibiotic X-14547A

K. Nicolaou, R. Magolda, R. Dolle, 1985 .

Synthesis of 4,5-dihydroazepine-3,6-dicarboxylate derivatives by stereoselective ring expansion-nucleophilic addition to 4-.alpha.-chloroalkyl-1,4-dihydropyridine-3,5-dicarboxylates

J. Springer, J. Baldwin, D. Claremon, 1984 .

Organolithium addition to aldehyde dimethylhydrazones: a highly diastereocontrolled synthesis of threo 2-amino alcohols and (1R,2R)-(−)-norpseudoephedrine

B. T. Phillips, P. Lumma, D. Claremon, 1986 .

Hantzsch 1,2,3,4-tetrahydropyridines related to calcium antagonists. Two synthetic approaches.

S. D. Young, D. Claremon, 1985 .

Total synthesis of ionophore antibiotic X-14547A. 2. Coupling of the tetrahydropyran and tetrahydroindan systems and construction of the butadienyl and ketopyrrole moieties

K. Nicolaou, R. Magolda, D. Claremon, 1981 .

A mild method for the synthesis of 2-ketopyrroles from carboxylic acids

K. Nicolaou, D. Claremon, D. Papahatjis, 1981 .

Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.

N. Liverton, C. Claiborne, K. Nguyen, 2007, Bioorganic & medicinal chemistry letters.

N-Phenylselenophthalimide. A useful reagent for the facile transformation of (1) carboxylic acids into either selenol esters or amides and (2) alcohols into alkyl phenyl selenides

K. Nicolaou, D. Claremon, P. Grieco, 1981 .

Total synthesis of ionophore antibiotic X-14547A. 1. Enantioselective synthesis of the tetrahydropyran and tetrahydroindan building blocks

K. Nicolaou, R. Dolle, D. Claremon, 1981 .

Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.

A. M. Lefer, E. Smith, R. Magolda, 1980, Proceedings of the National Academy of Sciences of the United States of America.

Total synthesis of (.+-.)-zoapatanol

K. Nicolaou, D. Claremon, W. E. Barnette, 1980 .

Antiarrhythmic efficacy of combined I(Ks) and beta-adrenergic receptor blockade.

N. Liverton, H. Selnick, J. Lynch, 2002, The Journal of pharmacology and experimental therapeutics.

4-Oxospiro[benzopyran-2,4'-piperidines] as class III antiarrhythmic agents. Pharmacological studies on 3,4-dihydro-1'-[2-(benzofurazan-5-yl)- ethyl]-6-methanesulfonamidospiro[(2H)-1-benzopyran-2,4'-piperidin]-4-on e (L-691,121).

B. T. Phillips, J. Baldwin, C. N. Habecker, 1992, Journal of medicinal chemistry.

Discovery of Potent Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 Using a Novel Growth-Based Protocol of in Silico Screening and Optimization in CONTOUR

Yi Zhao, Robert Cain, Yajun Zheng, 2019, J. Chem. Inf. Model..

Orally efficacious NR2B-selective NMDA receptor antagonists.

Kenneth D Anderson, R. Freidinger, N. Liverton, 2003, Bioorganic & medicinal chemistry letters.

In Vivo Canine Cardiac Electrophysiologic Profile of 1,4‐Benzodiazepine Iks Blockers

A. Tebben, H. Selnick, J. Lynch, 2003, Journal of cardiovascular pharmacology.

Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents.

R. Freidinger, N. Liverton, C. Dieckhaus, 2003, Bioorganic & medicinal chemistry letters.

Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.

Wei Zhao, Joan Guo, David A Claremon, 2011, ACS medicinal chemistry letters.

Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.

R. Gregg, Suresh B. Singh, H. Nar, 2010, Bioorganic & medicinal chemistry letters.

Spirocyclic ureas: orally bioavailable 11 beta-HSD1 inhibitors identified by computer-aided drug design.

Suresh B. Singh, D. Claremon, C. Tice, 2010, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.

R. Freidinger, N. Liverton, J. Mccauley, 2009, Bioorganic & medicinal chemistry letters.